Call Girls Aurangabad Just Call 8250077686 Top Class Call Girl Service Available
Rituximab in Nephrology (Different Uses & Available Evidence) - Dr. Gawad
1. Rituximab in Nephrology
Different Uses & Available Evidence
Mohammed Abdel Gawad
Nephrology Specialist
Kidney & Urology Center (KUC)
Alexandria – EGY
drgawad@gmail.com
5th - Feb - 2018
2. To get the presentation with full animations and
videos please contact me on
drgawad@gmail.com
For more presentations visit
www.NephroTubeCNE.com
10. Arthritis Rheum. 2012 Apr;64(4):1215-26
144 patients with biopsy proven class III or IV LN
There was no significant difference
between the renal response rates at week 52 in
the rituximab or placebo arms
18. Methylprednisolone
pulse (500 mg/m2)
followed by RTX
(1000 mg/1.73 m2)
at days 1 and 15
MMF
(1200 mg/m2/day)
Prednisolone was rapidly tapered, with median
dose of 0.3, 0.10 and 0.0 mg/kg/day at 3, 6 and 12
months respectively
2018 Jan;33(1):111-116
22. 2013 May;22(6):574-82
At 6 months, 11/18 patients reached renal CR and 2/18 PR
5 patients failed to show CR or PR despite peripheral B
lymphocyte count depletion, and progressed to ESRD
23. 2013 Jan;28(1):106-11
Out of 233 reports, we selected 26 for analysis, which
described 300 patients with a mean follow-up of 60 weeks
24. 2013 Jan;28(1):106-11
Out of 233 reports, we selected 26 for analysis, which
described 300 patients with a mean follow-up of 60 weeks
25. 2013 Jan;28(1):106-11
Out of 233 reports, we selected 26 for analysis, which
described 300 patients with a mean follow-up of 60 weeks
26. 2013 Jan;28(1):106-11
Out of 233 reports, we selected 26 for analysis, which
described 300 patients with a mean follow-up of 60 weeks
30. RCT for relapsing disease have not been performed.
The long-term efficacy and toxicity of rituximab have not
been defined.
No suggestion or
recommendation
for Rituximab.
31. Disease Rituximab use
LN (intiation of remission) • In black
• Inversely related to BMI
• It may allow steroid sparing in children
LN (resistant) • It can be used but needs RCTs
LN (relapse) • No evidence
ANCA vasculitis (initiation) Not inferior to cyclophosphamide
ANCA vasculitis (relapse) Superior to cyclophosphamide
ANCA vasculitis (resistant) It can be used but needs RCTs
ANCA vasculitis (maintenance) Superior to azathioprine
Key Points
39. 2015 Jun;74(6):1178-8
RITUXVAS trial follow up
Relapses occurred in seven patients in the rituximab group
(21%) and two in the control group (18%) (p=1.00)
53. March, 7, 2017; 18: 112
h t t p : / / c l i n i c a l t r i a l s . g o v / c t 2 / s h o w /NCT01697267.
54. Disease Rituximab use
LN (intiation of remission) • In black
• Inversely related to BMI
• It may allow steroid sparing in children
LN (resistant) • It can be used but needs RCTs
LN (relapse) • No evidence
ANCA vasculitis (initiation) • Not inferior to cyclophosphamide
ANCA vasculitis (relapse) • Superior to cyclophosphamide
ANCA vasculitis (resistant) • It can be used but needs RCTs
ANCA vasculitis (maintenance) • Superior to azathioprine
Key Points
67. MEmbranous Nephropathy Trial Of Rituximab
(MENTOR)
Sequential Therapy With Tacrolimus and
Rituximab in Primary Membranous Nephropathy
(STARMEN)
Rituximab Versus Steroids and Cyclophosphamide
in the Treatment of Idiopathic Membranous
Nephropathy (RI-CYCLO)
68. Disease Rituximab use
MN • Superior to NIAT alone
• Not inferior to cyclophosphamide with better safety
profile
• Waiting results of major ongoing trials
MCD • Children: SSNS
• Adults: FR, SD, SR (needs RCTs)
FSGS SD but not SR (case reports)
MPGN • In ig-associated MPGN, particularly in:
monoclonal gammopathy
chronic lymphocytic leukemia
cryoglobulinemia with or without HCV
• Not in C3GN or DDD
IgA Case reports
Anti GBM disease Case reports
Key Points
74. 2017 Feb; 10(1): 16–19
Outcomes of all adult MCD patients treated with
RTX for FRNS between 2008 and 2015were
retrospectively analyzed
Thirteen patients received RTX
The rate of relapse was reduced from 4 to 0.4/year
(Wilcoxon signed rank P ≤ 0.05)
79. Several case reports have described successful use
of rituximab in adult patients with steroid-
dependent but not steroid-resistant FSGS
Oncotarget. 2017 Oct 15;8(55):93438-93443
Clin J Am Soc Nephrol. 2009 Aug;4(8):1317-23
Intern Med. 2012;51(7):759-62
Wien Klin Wochenschr. 2013 Jun;125(11-12):328-33
80. Disease Rituximab use
MN • Superior to NIAT alone
• Not inferior to cyclophosphamide with better safety
profile
• Waiting results of major ongoing trials
MCD • Children: SSNS
• Adults: FR, SD, SR (needs RCTs)
FSGS • SD but not SR (case reports)
MPGN • In ig-associated MPGN, particularly in:
monoclonal gammopathy
chronic lymphocytic leukemia
cryoglobulinemia with or without HCV
• Not in C3GN or DDD
IgA Case reports
Anti GBM disease Case reports
Key Points
82. Studies of rituximab treatment in
idiopathic MPGN
Rituximab seems to be effective in immunoglobulin-
associated MPGN, particularly in those cases
associated with:
• monoclonal gammopathy
• chronic lymphocytic leukemia
• cryoglobulinemia with or without HCV
Biomed Res Int. May 9; 2017: 2180508.
83. Studies of rituximab treatment in
idiopathic MPGN
Biomed Res Int. May 9; 2017: 2180508.
84. Reports on rituximab treatment in
C3GN and DDD
Biomed Res Int. May 9; 2017: 2180508.
88. Rituximab for Severe Mixed
Cryoglobulinemia
N Engl J Med. 2013 Sep;369(11):1035-45
Autoimmun Rev. 2011 Jun;10(8):444-54
Nephron Clin Pract. 2011;119(2)
Immunosuppressive therapy including rituximab or, if
unavailable, cyclophosphamide
After disease stabilization, patients should receive
concurrent therapy for the underlying disorder
Exceptions to this general principle include mixed
cryoglobulinemia due to HIV or HBV infections;
(antiviral therapy should always be initiated before or
at the same time as immunosuppressive therapy)
89. Disease Rituximab use
MN • Superior to NIAT alone
• Not inferior to cyclophosphamide with better safety
profile
• Waiting results of major ongoing trials
MCD • Children: SSNS
• Adults: FR, SD, SR (needs RCTs)
FSGS SD but not SR (case reports)
MPGN • In Ig-associated MPGN, particularly in:
monoclonal gammopathy
chronic lymphocytic leukemia
cryoglobulinemia with or without HCV
• Not in C3GN or DDD
IgA Case reports
Anti GBM disease Case reports
Key Points
93. Anti-GBM antibody disease
Semin Arthritis Rheum. 2013 Jun;42(6):567-72
J Autoimmun. 2015;60:74.
Patients who either refuse or, because of severe side
effects, need to discontinue cyclophosphamide may
receive rituximab therapy or, alternatively, MMF.
Several reported cases
94. Anti-GBM antibody disease
Semin Arthritis Rheum. 2013 Jun;42(6):567-72
J Autoimmun. 2015;60:74.
initial seven consecutive days of
plasma exchange and glucocorticoids
two rituximab
doses
another seven days of
plasma exchange
second of the two
doses of rituximab
95. Disease Rituximab use
MN • Superior to NIAT alone
• Not inferior to cyclophosphamide with better safety
profile
• Waiting results of major ongoing trials
MCD • Children: SSNS
• Adults: FR, SD, SR (needs RCTs)
FSGS SD but not SR (case reports)
MPGN • In Ig-associated MPGN, particularly in:
monoclonal gammopathy
chronic lymphocytic leukemia
cryoglobulinemia with or without HCV
• Not in C3GN or DDD
IgA • Case reports
Anti GBM disease • Case reports
Key Points
97. Refractory/ Relapsing TTP
Refractory TTP:
Progression of clinical symptoms or persistent
thrombocytopenia despite seven daily PEX procedures
Relapsing TTP:
Episode of acute TTP more than
30 d after remission, and occurs in 20–50% of cases.
04
British Journal of Haematology, 2012, 158, 323–335.
100. Rituximab
On admission, in conjunction with PEX
and steroids if:
acute idiopathic TTP with
neurological/cardiac pathology, which
are associated with a high mortality (1B).
Refractory or
Relapsing
immune-
mediated TTP
(1B).
Acquired TTP Treatment
Other Options
02
British Journal of Haematology, 2012, 158, 323–335.
105. Disease Rituximab use
TTP (refractory, relapse) • Good evidence to use
TTP (induction of remission) • Ongoing trend
Tx • Induction/desensitization in Ab incompatible Tx
• Acute and chronic ABMR ??!!
• Recurrent GN
• PTLD
Key Points
113. Disease Rituximab use
TTP (refractory, relapse) Good evidence to use
TTP (induction of remission) Ongoing trend
Tx • Induction/desensitization in Ab incompatible Tx
• Acute and chronic ABMR ??!!
• Recurrent GN
• PTLD
Key Points
115. • Rituximab is a chimeric monoclonal antibody
directed against the CD20 antigen on the
surface of immature and mature B cells.
• It is used in clinical nephrology related
diseases & renal transplantation.
• It is safe and well tolerated in most.
Key Points
116. • Long-term use may be complicated by
hypogammaglobulinaemia and increased
infectious complications.
• Optimal dosing is unclear.
• The development of bio-similars and dosing
targeted to B-cell response may reduce cost.
Key Points
117. Disease Rituximab use
LN (intiation of remission) • In black
• Inversely related to BMI
• It may allow steroid sparing in children
LN (resistant) • It can be used but needs RCTs
LN (relapse) • No evidence
ANCA vasculitis (initiation) • Not inferior to cyclophosphamide
ANCA vasculitis (relapse) • Superior to cyclophosphamide
ANCA vasculitis (resistant) • It can be used but needs RCTs
ANCA vasculitis (maintenance) • Superior to azathioprine
Key Points
118. Disease Rituximab use
MN • Superior to NIAT alone
• Not inferior to cyclophosphamide with better safety
profile
• Waiting results of major ongoing trials
MCD • Children: SSNS
• Adults: FR, SD, SR (needs RCTs)
FSGS SD but not SR (case reports)
MPGN • In Ig-associated MPGN, particularly in:
monoclonal gammopathy
chronic lymphocytic leukemia
cryoglobulinemia with or without HCV
• Not in C3GN or DDD
IgA • Case reports
Anti GBM disease • Case reports
Key Points
119. Disease Rituximab use
TTP (refractory, relapse) • Good evidence to use
TTP (induction of remission) • Ongoing trend
Tx • Induction/desensitization in Ab incompatible Tx
• Acute and chronic ABMR ??!!
• Recurrent GN
• PTLD
Key Points